These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 27416373)

  • 1. What makes oncogenes mutually exclusive?
    Cisowski J; Bergo MO
    Small GTPases; 2017 Jul; 8(3):187-192. PubMed ID: 27416373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.
    Cisowski J; Sayin VI; Liu M; Karlsson C; Bergo MO
    Oncogene; 2016 Mar; 35(10):1328-33. PubMed ID: 26028035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying Epistasis in Cancer Genomes: A Delicate Affair.
    van de Haar J; Canisius S; Yu MK; Voest EE; Wessels LFA; Ideker T
    Cell; 2019 May; 177(6):1375-1383. PubMed ID: 31150618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?
    Felsher DW
    Cancer Res; 2008 May; 68(9):3081-6; discussion 3086. PubMed ID: 18451131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells.
    Zecchin D; Arena S; Martini M; Sassi F; Pisacane A; Di Nicolantonio F; Bardelli A
    Hum Mutat; 2013 Feb; 34(2):330-7. PubMed ID: 23292961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. If you can't beat me, join me: collaborating oncogenes circumventing senescence and causing cancer.
    Possik PA; Peeper DS
    Pigment Cell Melanoma Res; 2011 Aug; 24(4):586-7. PubMed ID: 22489324
    [No Abstract]   [Full Text] [Related]  

  • 8. Oncogenic activating mutations are associated with local copy gain.
    Modrek B; Ge L; Pandita A; Lin E; Mohan S; Yue P; Guerrero S; Lin WM; Pham T; Modrusan Z; Seshagiri S; Stern HM; Waring P; Garraway LA; Chant J; Stokoe D; Cavet G
    Mol Cancer Res; 2009 Aug; 7(8):1244-52. PubMed ID: 19671679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogene-induced senescence: a double edged sword in cancer.
    Liu XL; Ding J; Meng LH
    Acta Pharmacol Sin; 2018 Oct; 39(10):1553-1558. PubMed ID: 29620049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery.
    Peng J; Lin J; Qiu M; Zhao Y; Deng Y; Shao J; Ding P; Zhang H; Wan D; Lu Z; Pan Z
    Tumour Biol; 2017 Jul; 39(7):1010428317709638. PubMed ID: 28671043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity.
    Petti C; Molla A; Vegetti C; Ferrone S; Anichini A; Sensi M
    Cancer Res; 2006 Jul; 66(13):6503-11. PubMed ID: 16818621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity.
    Kaji T; Yamasaki O; Takata M; Otsuka M; Hamada T; Morizane S; Asagoe K; Yanai H; Hirai Y; Umemura H; Iwatsuki K
    J Dermatol Sci; 2017 Jan; 85(1):51-57. PubMed ID: 27771229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Aging and Cancer: Role of miRNA in Tumor Microenvironment.
    Sandiford OA; Moore CA; Du J; Boulad M; Gergues M; Eltouky H; Rameshwar P
    Adv Exp Med Biol; 2018; 1056():137-152. PubMed ID: 29754179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEMCover: integrated analysis of mutual exclusivity and functional network reveals dysregulated pathways across multiple cancer types.
    Kim YA; Cho DY; Dao P; Przytycka TM
    Bioinformatics; 2015 Jun; 31(12):i284-92. PubMed ID: 26072494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How do mutated oncogenes and tumor suppressor genes cause cancer?
    Grandér D
    Med Oncol; 1998 Apr; 15(1):20-6. PubMed ID: 9643526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SSA-ME Detection of cancer driver genes using mutual exclusivity by small subnetwork analysis.
    Pulido-Tamayo S; Weytjens B; De Maeyer D; Marchal K
    Sci Rep; 2016 Nov; 6():36257. PubMed ID: 27808240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of Reactive Oxygen Species in Cells Undergoing Oncogene-Induced Senescence.
    Ameziane-El-Hassani R; Dupuy C
    Methods Mol Biol; 2017; 1534():139-145. PubMed ID: 27812875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.
    Morkel M; Riemer P; Bläker H; Sers C
    Oncotarget; 2015 Aug; 6(25):20785-800. PubMed ID: 26299805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying Driver Genomic Alterations in Cancers by Searching Minimum-Weight, Mutually Exclusive Sets.
    Lu S; Lu KN; Cheng SY; Hu B; Ma X; Nystrom N; Lu X
    PLoS Comput Biol; 2015 Aug; 11(8):e1004257. PubMed ID: 26317392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Too much or too little: harnessing senescence to control oncogene-driven cancer.
    Hannan KM; Pearson RB
    Cell Cycle; 2012 Sep; 11(17):3147-8. PubMed ID: 22894904
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.